Table 1.
Baseline demographic and clinical characteristics
| Age (years) | Total sample (n = 59) | Study completers (n = 29) |
|---|---|---|
| Mean (SD) | 33.6 (9.1) | 33.2 (10.3) |
| Median (range) | 34 (21–57) | 30 (21–57) |
| Gender, n (%) | ||
| Male | 39 (73.6) | 19 (65.5) |
| Female | 14 (26.4) | 10 (34.5) |
| Disease duration (years) | n = 36 | n = 29 |
| Mean (SD) | 9.2 (9.9) | 9.9 (11.0) |
| Median (range) | 5.5 (0–41) | 5.5 (0–39) |
| Inpatient admissions in the last year, n (%) | ||
| Yes | 11 (20.8) | NA |
| Previous antipsychotic treatment, n (%) | n = 53 | |
| Chlorpromazine | 6(11.3) | NA |
| Haloperidol | 12(22.6) | NA |
| Risperidone | 22(41.5) | NA |
| Assessments | Mean (SD) | |
| PANSS (n = 53) | ||
| Positive scale | 14.1 (4.8) | 13.2 (5.1) |
| Negative scale | 18.3 (5.6) | 18.5 (6.6) |
| Total | 63.5 (14.1) | 61.1 (15.7) |
| CGI-S (n = 53) | 3.6 (0.9) | 3.4 (0.8) |
| DAI-10 (n = 51) | 2.8 (4.7) | 2.2 (5.0) |
Abbreviations: PANSS, Positive and Negative Syndromes Scale; DAI, Drug Attitude Inventory; CGI-S, Clinician’s Global Impression of Disease Severity; SD, standard deviation; NA, not available.